Stability & Variability of Lipid-derived Molecules in Sweat
Conditions
Keywords
oxygenated lipids, metabolic profiling, sphingoid bases, ceramides, endocannabinoids, non-invasive sampling
Brief summary
The purpose of this study is to see what the differences are in sweat (amount and small molecule content) collected from different sites of the body and by different methods of sweat stimulation. Additionally, the investigators want to know whether the amount and small molecule content of the sweat is the same in an individual over time, and the same across individuals at a given time. Finally, the investigators want to know how consumption of over-the-counter anti-inflammatory drugs such as ibuprofen will affect the inflammatory mediator content of sweat and how that compares to blood. This information will help to better understand the composition and behavior of sweat and assess its potential utility as a routine clinical tool in skin research.
Detailed description
Subjects will participate in 4 study day visits that will be scheduled about 1- week apart. During the first study visit, the investigators will compare sweat collected following pharmacological stimulation of sweating (using the drug pilocarpine) to sweat collected following physiological stimulation of sweating (using a stationary bicycle). During the second study visit, the investigators will collect sweat following stimulation of sweating by the drug pilocarpine from the inner part of the forearm (near the wrist) and also the upper surface of the thigh (near the knee). During the third study visit, the investigators will collect sweat following stimulation of sweating by the drug pilocarpine from the inner part of both forearms (near the wrist). During the fourth study visit, the investigators will collect a sweat sample following stimulation of sweating by the drug pilocarpine from the inner part of the forearm (near the wrist) and a blood sample (about one teaspoon) from the other arm. After blood and sweat collection, participants will consume 400 mg (two tablets) of ibuprofen. The investigators will then collect blood and sweat from 30 minutes, 2 hours and 4 hours after participants consume the ibuprofen.
Interventions
DRUGIbuprofen
400 mg ibuprofen given to inhibit cyclooxygenase metabolism
OTHERPhysiological induction of sweating
15 minutes exercise at 60-80% oxygen consumption to induce sweating
DRUGPilocarpine
Iontophoresis with a 1.5 milliampere (mA) current using a gel disc containing a 5% pilocarpine nitrate solution to induce sweating
Sponsors
University of California, Davis
USDA, Western Human Nutrition Research Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
20 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
* 20-40 y * Male * Weight \> 110 pounds
Exclusion criteria
* Diagnosed active chronic diseases for which the individual is currently taking daily medication, including but not limited to: * Diabetes mellitus * Cardiovascular disease * Cancer * Gastrointestinal disorders * Kidney disease * Liver disease * Bleeding disorders * Asthma * Autoimmune disorders * Hypertension * Osteoporosis * Recent minor surgery (within 4 wk) or major surgery (within 16 wk) * Recent antibiotic therapy (within 4 wk) * Recent hospitalization (within 4 wk) * Use of over-the-counter or prescription medications at the time of the study that directly affect endpoints of interest (e.g. hyperlipidemia, glycemic control, steroids, statins, anti-inflammatory agents, and weight loss aids) * Adults who are not able to consent * Under current medical supervision * Ibuprofen intolerance or allergy * Those with a bleeding disorder * Current enrollee in a clinical research study. * Individuals with blood clotting or platelet defect disorders * Individuals with orthopedic limitations or cardiovascular risk that preclude participation in the physiological stimulation of sweat by light exercise portion of the study * Individuals who are trained athletes or that regularly perform physical activity defined as vigorous by the Centers for Disease Control and Prevention
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | measured at four timepoints at study visit 4, detected lipid mediator concentrations for first timepoint reported | Approximately 100 lipid mediators will be measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Assayed lipid mediators include oxygenated lipids, endocannabinoids, and endocannabinoid-like molecules. |
| Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | measured at study visit 1, detected lipid mediator concentrations reported | Approximately 150 lipid mediators will be measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Assayed lipid mediators include oxygenated lipids, endocannabinoids and endocannabinoid-like molecules, and sphingolipids. |
| Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | measured at study visit 1, detected lipid mediator concentrations reported | Approximately 150 lipid mediators will be measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Assayed lipid mediators include oxygenated lipids, endocannabinoids and endocannabinoid-like molecules, and sphingolipids. |
| Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | measured at study visit 2, detected lipid mediator concentrations reported | Approximately 150 lipid mediators will be measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Assayed lipid mediators include oxygenated lipids, endocannabinoids and endocannabinoid-like molecules, and sphingolipids. |
| Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | measured at study visit 1, 2 and 3; detected lipid mediator concentrations for study visit 1 reported | Approximately 150 lipid mediators will be measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Assayed lipid mediators include oxygenated lipids, endocannabinoids and endocannabinoid-like molecules, and sphingolipids. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Plasma Ibuprofen Concentrations | measured at four timepoints at study visit 4 | Plasma concentration of ibuprofen prior to and 30 min, 2 hr and 4 hr after oral administration |
| Change in Sweat Ibuprofen Concentrations | measured at four timepoints at study visit 4 | Sweat concentration of ibuprofen prior to and 30 min, 2 hr and 4 hr after oral administration |
| Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | measured at four timepoints at study visit 4, detected lipid mediator concentrations for first timepoint reported | Approximately 100 lipid mediators will be measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Assayed lipid mediators include oxygenated lipids, endocannabinoids, and endocannabinoid-like molecules. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Single Group All subjects will participate in 4 study day visits in the same order.
1. compare sweat collected following pharmacological stimulation of sweating (using the drug pilocarpine) to sweat collected following physiological induction of sweating (exercise on a stationary bicycle).
2. compare sweat collected following stimulation of sweating by the drug pilocarpine from the inner part of the forearm (near the wrist) to upper surface of thigh (near the knee).
3. collect sweat following stimulation of sweating by the drug pilocarpine from the inner part of both forearms (near the wrist).
4. collect blood and sweat samples before and 30 minutes, 2 hours and 4 hours after consumption of 400 mg of ibuprofen.
Ibuprofen: 400 mg ibuprofen given to inhibit cyclooxygenase (COX) metabolism
Physiological induction of sweating: 15 minutes exercise at 60-80% oxygen consumption to induce sweating
Pilocarpine: Iontophoresis with a 1.5 milliampere (mA) current using a gel disc containing a | 14 |
| Total | 14 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Subject dismissed | 1 |
Baseline characteristics
| Characteristic | Single Group | — |
|---|---|---|
| Age, Categorical <=18 years | 0 Participants | — |
| Age, Categorical >=65 years | 0 Participants | — |
| Age, Categorical Between 18 and 65 years | 14 Participants | — |
| Body Mass Index | 25.8 kilograms per square meter STANDARD_DEVIATION 5 | — |
| Height | 179.2 centimeters STANDARD_DEVIATION 6.2 | — |
| Perceived Exercise Intensity | 1.6 units on a scale STANDARD_DEVIATION 0.5 | — |
| Race and Ethnicity Not Collected | — | — Participants |
| Region of Enrollment United States | 14 participants | — |
| Sex: Female, Male Female | 0 Participants | — |
| Sex: Female, Male Male | 14 Participants | — |
| Weight | 82.6 kilograms STANDARD_DEVIATION 15.9 | — |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 14 |
| other Total, other adverse events | 0 / 14 |
| serious Total, serious adverse events | 0 / 14 |
Outcome results
Primary
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
Approximately 150 lipid mediators will be measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Assayed lipid mediators include oxygenated lipids, endocannabinoids and endocannabinoid-like molecules, and sphingolipids.
Time frame: measured at study visit 2, detected lipid mediator concentrations reported
Population: Of the 14 subjects recruited for this study, only 4 provided usable data for this primary outcome.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 13-HOTrE | 5.2 picomoles per milliliter | Standard Deviation 1 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 8-HETE | 0.17 picomoles per milliliter | Standard Deviation 0.066 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 9-HETE | 0.12 picomoles per milliliter | Standard Deviation 0.043 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 11-HETE | 0.12 picomoles per milliliter | Standard Deviation 0.075 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 12-HETE | 0.31 picomoles per milliliter | Standard Deviation 0.14 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 15-HETE | 0.26 picomoles per milliliter | Standard Deviation 0.28 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 12-HEPE | 0.13 picomoles per milliliter | Standard Deviation 0.057 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 9,10-e-DiHO | 35 picomoles per milliliter | Standard Deviation 5.5 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | PEA | 18 picomoles per milliliter | Standard Deviation 6.4 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | SEA | 18 picomoles per milliliter | Standard Deviation 5.8 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | LEA | 0.078 picomoles per milliliter | Standard Deviation 0.039 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | aLEA | 0.022 picomoles per milliliter | Standard Deviation 0.005 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 9-HODE | 19 picomoles per milliliter | Standard Deviation 9.9 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 13-HODE | 48 picomoles per milliliter | Standard Deviation 24 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 8,9-DiHETrE | 0.62 picomoles per milliliter | Standard Deviation 0.45 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 9-HOTrE | 1.8 picomoles per milliliter | Standard Deviation 0.54 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 5-HETE | 0.067 picomoles per milliliter | Standard Deviation 0.059 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 9,10-DiHOME | 2.9 picomoles per milliliter | Standard Deviation 0.89 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 12,13-DiHOME | 2.4 picomoles per milliliter | Standard Deviation 0.69 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 9,10-DiHODE | 0.46 picomoles per milliliter | Standard Deviation 0.095 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 12,13-DiHODE | 0.7 picomoles per milliliter | Standard Deviation 0.13 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 15,16-DiHODE | 0.99 picomoles per milliliter | Standard Deviation 0.31 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 5,6-DiHETrE | 2.7 picomoles per milliliter | Standard Deviation 1.2 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 11,12-DiHETrE | 0.19 picomoles per milliliter | Standard Deviation 0.072 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 14,15-DiHETrE | 0.19 picomoles per milliliter | Standard Deviation 0.087 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 9,10-EpOME | 1.7 picomoles per milliliter | Standard Deviation 0.54 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 12,13-EpOME | 1.6 picomoles per milliliter | Standard Deviation 0.47 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 9,10-EpODE | 0.8 picomoles per milliliter | Standard Deviation 0.66 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 12,13-EpODE | 0.25 picomoles per milliliter | Standard Deviation 0.14 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 15,16-EpODE | 0.95 picomoles per milliliter | Standard Deviation 0.45 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 9-KODE | 21 picomoles per milliliter | Standard Deviation 17 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 13-KODE | 9.3 picomoles per milliliter | Standard Deviation 7.3 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 12,13-Ep-9-KODE | 3.3 picomoles per milliliter | Standard Deviation 1.4 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 5-KETE | 0.04 picomoles per milliliter | Standard Deviation 0.018 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | LTB5 | 0.088 picomoles per milliliter | Standard Deviation 0.068 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 10-Nitrooleate | 0.12 picomoles per milliliter | Standard Deviation 0.14 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 10-Nitrolinoleate | 0.16 picomoles per milliliter | Standard Deviation 0.019 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | PGE1 | 0.18 picomoles per milliliter | Standard Deviation 0.15 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | PGE2 | 0.36 picomoles per milliliter | Standard Deviation 0.38 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | PGF2a | 0.44 picomoles per milliliter | Standard Deviation 0.45 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | PGE3 | 0.15 picomoles per milliliter | Standard Deviation 0.14 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | Sum TriHOMEs | 36 picomoles per milliliter | Standard Deviation 14 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | OEA | 0.31 picomoles per milliliter | Standard Deviation 0.24 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | Dihomo GLA EA | 0.00037 picomoles per milliliter | Standard Deviation 0.0058 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | AEA | 0.013 picomoles per milliliter | Standard Deviation 0.005 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | DEA | 0.053 picomoles per milliliter | Standard Deviation 0.061 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 1-OG | 200 picomoles per milliliter | Standard Deviation 88 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 2-OG | 37 picomoles per milliliter | Standard Deviation 16 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 1-LG | 81 picomoles per milliliter | Standard Deviation 41 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 2-LG | 2.1 picomoles per milliliter | Standard Deviation 0.6 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 1-AG | 13 picomoles per milliliter | Standard Deviation 5.4 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 2-AG | 4.2 picomoles per milliliter | Standard Deviation 0.72 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | NO-Gly | 0.23 picomoles per milliliter | Standard Deviation 0.14 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | NA-Gly | 0.02 picomoles per milliliter | Standard Deviation 0.013 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | C14 Ceramide | 0.24 picomoles per milliliter | Standard Deviation 0.15 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | C16 Ceramide | 1.5 picomoles per milliliter | Standard Deviation 1.2 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | C18 Ceramide | 0.31 picomoles per milliliter | Standard Deviation 0.25 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | C20 Ceramide | 0.36 picomoles per milliliter | Standard Deviation 0.32 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | C24 Ceramide | 1 picomoles per milliliter | Standard Deviation 0.99 |
| Single Group | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 18:1 Sphingosine | 2.2 picomoles per milliliter | Standard Deviation 4.5 |
Primary
Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
Approximately 100 lipid mediators will be measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Assayed lipid mediators include oxygenated lipids, endocannabinoids, and endocannabinoid-like molecules.
Time frame: measured at four timepoints at study visit 4, detected lipid mediator concentrations for first timepoint reported
Population: Of the 14 subjects recruited for this study, only 9 provided usable data for this primary outcome.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Single Group | Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 15(16)-EpODE | 3.95 picomoles per milliliter |
| Single Group | Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 9(10)-EpODE | 1.02 picomoles per milliliter |
| Single Group | Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 13-KODE | 1.89 picomoles per milliliter |
| Single Group | Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | LEA | 1.19 picomoles per milliliter |
| Single Group | Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | aLEA | 0.0968 picomoles per milliliter |
| Single Group | Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | NA-Gly | 0.833 picomoles per milliliter |
| Single Group | Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | PGE1 | 0.126 picomoles per milliliter |
| Single Group | Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | PGE2 | 0.159 picomoles per milliliter |
| Single Group | Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | PGF2a | 5.47 picomoles per milliliter |
| Single Group | Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 13-HODE | 23 picomoles per milliliter |
| Single Group | Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 9-HODE | 8.77 picomoles per milliliter |
| Single Group | Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 13-HOTE | 1.56 picomoles per milliliter |
| Single Group | Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 9-HOTE | 1.19 picomoles per milliliter |
| Single Group | Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 15-HETE | 0.861 picomoles per milliliter |
| Single Group | Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 12-HETE | 1.31 picomoles per milliliter |
| Single Group | Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 11-HETE | 0.408 picomoles per milliliter |
| Single Group | Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 5-HETE | 0.425 picomoles per milliliter |
| Single Group | Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 17-HDoHE | 2.55 picomoles per milliliter |
| Single Group | Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 9,10-e-DiHO | 10.4 picomoles per milliliter |
| Single Group | Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 12,13-DiHOME | 4.13 picomoles per milliliter |
| Single Group | Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 9,10-DiHOME | 4.44 picomoles per milliliter |
| Single Group | Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 15,16-DiHODE | 15 picomoles per milliliter |
| Single Group | Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 12,13-DiHODE | 1.77 picomoles per milliliter |
| Single Group | Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 9,10-DiHODE | 0.458 picomoles per milliliter |
| Single Group | Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 14,15-DiHETrE | 1.17 picomoles per milliliter |
| Single Group | Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 11,12-DiHETrE | 1.11 picomoles per milliliter |
| Single Group | Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 5,6-DiHETrE | 0.406 picomoles per milliliter |
| Single Group | Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 17,18-DiHETE | 20.2 picomoles per milliliter |
| Single Group | Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 19,20-DiHDoPA | 1.91 picomoles per milliliter |
| Single Group | Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | Sum TriHOMEs | 7.88 picomoles per milliliter |
| Single Group | Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 9(10)-EpO | 9.96 picomoles per milliliter |
| Single Group | Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 12(13)-EpOME | 4.1 picomoles per milliliter |
| Single Group | Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 9(10)-EpOME | 1.12 picomoles per milliliter |
| Single Group | Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 9-KODE | 3.09 picomoles per milliliter |
| Single Group | Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | OEA | 4.14 picomoles per milliliter |
| Single Group | Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | Dihomo GLA EA | 0.168 picomoles per milliliter |
| Single Group | Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | AEA | 0.627 picomoles per milliliter |
| Single Group | Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | DEA | 0.298 picomoles per milliliter |
| Single Group | Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | DHEA | 0.76 picomoles per milliliter |
| Single Group | Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | NO-Gly | 3.5 picomoles per milliliter |
| Single Group | Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | OG | 393 picomoles per milliliter |
| Single Group | Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | LG | 238 picomoles per milliliter |
| Single Group | Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | AG | 20.7 picomoles per milliliter |
Primary
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
Approximately 150 lipid mediators will be measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Assayed lipid mediators include oxygenated lipids, endocannabinoids and endocannabinoid-like molecules, and sphingolipids.
Time frame: measured at study visit 1, detected lipid mediator concentrations reported
Population: Of the 14 subjects recruited for this study, only 4 provided usable data for this primary outcome.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 9-HETE | 0.12 picomoles per milliliter | Standard Deviation 0.083 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 11-HETE | 0.2 picomoles per milliliter | Standard Deviation 0.27 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 9,10-DiHOME | 2.6 picomoles per milliliter | Standard Deviation 0.73 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 12,13-DiHOME | 2.2 picomoles per milliliter | Standard Deviation 0.52 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 12,13-EpODE | 0.2 picomoles per milliliter | Standard Deviation 0.1 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 15,16-EpODE | 0.49 picomoles per milliliter | Standard Deviation 0.34 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 9-KODE | 11 picomoles per milliliter | Standard Deviation 9.2 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 13-KODE | 6 picomoles per milliliter | Standard Deviation 2.9 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 12,13-Ep-9-KODE | 2.6 picomoles per milliliter | Standard Deviation 0.94 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | aLEA | 0.11 picomoles per milliliter | Standard Deviation 0.14 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 2-OG | 46 picomoles per milliliter | Standard Deviation 47 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 1-LG | 110 picomoles per milliliter | Standard Deviation 82 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 2-LG | 2.6 picomoles per milliliter | Standard Deviation 1.3 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 1-AG | 10 picomoles per milliliter | Standard Deviation 12 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 9-HODE | 17 picomoles per milliliter | Standard Deviation 11 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 13-HODE | 81 picomoles per milliliter | Standard Deviation 42 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 9-HOTrE | 1.8 picomoles per milliliter | Standard Deviation 0.65 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 13-HOTrE | 2.6 picomoles per milliliter | Standard Deviation 1.1 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 5-HETE | 0.15 picomoles per milliliter | Standard Deviation 0.1 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 8-HETE | 0.23 picomoles per milliliter | Standard Deviation 0.21 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 12-HETE | 0.3 picomoles per milliliter | Standard Deviation 0.22 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 15-HETE | 0.32 picomoles per milliliter | Standard Deviation 0.2 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 12-HEPE | 0.15 picomoles per milliliter | Standard Deviation 0.11 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 9,10-e-DiHO | 36 picomoles per milliliter | Standard Deviation 13 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 9,10-DiHODE | 0.38 picomoles per milliliter | Standard Deviation 0.16 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 12,13-DiHODE | 0.34 picomoles per milliliter | Standard Deviation 0.14 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 15,16-DiHODE | 0.55 picomoles per milliliter | Standard Deviation 0.16 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 5,6-DiHETrE | 2.8 picomoles per milliliter | Standard Deviation 1.8 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 8,9-DiHETrE | 0.1 picomoles per milliliter | Standard Deviation 0.22 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 11,12-DiHETrE | 0.28 picomoles per milliliter | Standard Deviation 0.039 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 14,15-DiHETrE | 0.34 picomoles per milliliter | Standard Deviation 0.067 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 9,10-EpOME | 1.6 picomoles per milliliter | Standard Deviation 1.1 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 12,13-EpOME | 1.6 picomoles per milliliter | Standard Deviation 1.3 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 9,10-EpODE | 0.28 picomoles per milliliter | Standard Deviation 0.15 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 5-KETE | 0.1 picomoles per milliliter | Standard Deviation 0.12 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | LTB5 | 0.13 picomoles per milliliter | Standard Deviation 0.093 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 10-Nitrooleate | 0.75 picomoles per milliliter | Standard Deviation 1.2 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 10-Nitrolinoleate | 0.26 picomoles per milliliter | Standard Deviation 0.31 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | PGE1 | 0.11 picomoles per milliliter | Standard Deviation 0.046 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | PGE2 | 0.62 picomoles per milliliter | Standard Deviation 0.28 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | PGF2a | 0.27 picomoles per milliliter | Standard Deviation 0.15 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | PGE3 | 0.17 picomoles per milliliter | Standard Deviation 0.13 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | Sum TriHOMEs | 12 picomoles per milliliter | Standard Deviation 11 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | PEA | 47 picomoles per milliliter | Standard Deviation 65 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | SEA | 53 picomoles per milliliter | Standard Deviation 73 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | OEA | 0.55 picomoles per milliliter | Standard Deviation 0.46 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | LEA | 0.14 picomoles per milliliter | Standard Deviation 0.14 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | Dihomo GLA EA | 0.05 picomoles per milliliter | Standard Deviation 0.083 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | AEA | 0.14 picomoles per milliliter | Standard Deviation 0.19 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | DEA | 0.028 picomoles per milliliter | Standard Deviation 0.069 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 1-OG | 300 picomoles per milliliter | Standard Deviation 210 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 2-AG | 2.6 picomoles per milliliter | Standard Deviation 1.3 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | NO-Gly | 0.25 picomoles per milliliter | Standard Deviation 0.26 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | NA-Gly | 0.027 picomoles per milliliter | Standard Deviation 0.057 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | C14 Ceramide | 0.49 picomoles per milliliter | Standard Deviation 0.28 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | C16 Ceramide | 1.7 picomoles per milliliter | Standard Deviation 1.6 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | C18 Ceramide | 0.34 picomoles per milliliter | Standard Deviation 0.32 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | C20 Ceramide | 0.33 picomoles per milliliter | Standard Deviation 0.26 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | C24 Ceramide | 0.41 picomoles per milliliter | Standard Deviation 0.28 |
| Single Group | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 18:1 Sphingosine | 8.1 picomoles per milliliter | Standard Deviation 12 |
Primary
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
Approximately 150 lipid mediators will be measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Assayed lipid mediators include oxygenated lipids, endocannabinoids and endocannabinoid-like molecules, and sphingolipids.
Time frame: measured at study visit 1, detected lipid mediator concentrations reported
Population: Of the 14 subjects recruited for this study, only 7 provided usable data for this primary outcome.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | 9-HOTrE | 0.6 picomoles per milliliter | Standard Deviation 0.5 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | 8,9-DiHETrE | 0.24 picomoles per milliliter | Standard Deviation 0.25 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | 11,12-DiHETrE | 0.022 picomoles per milliliter | Standard Deviation 0.026 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | 14,15-DiHETrE | 0.041 picomoles per milliliter | Standard Deviation 0.018 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | 9,10-EpODE | 0.19 picomoles per milliliter | Standard Deviation 0.18 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | 12,13-EpODE | 0.019 picomoles per milliliter | Standard Deviation 0.014 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | 15,16-EpODE | 0.82 picomoles per milliliter | Standard Deviation 0.86 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | 10-Nitrolinoleate | 0.087 picomoles per milliliter | Standard Deviation 0.078 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | PGE1 | 0.85 picomoles per milliliter | Standard Deviation 1 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | PGF2a | 0.44 picomoles per milliliter | Standard Deviation 0.74 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | 15-deoxy PGJ2 | 0.046 picomoles per milliliter | Standard Deviation 0.036 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | Dihomo GLA EA | 0.0023 picomoles per milliliter | Standard Deviation 0.0036 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | AEA | 0.017 picomoles per milliliter | Standard Deviation 0.025 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | DEA | 0.015 picomoles per milliliter | Standard Deviation 0.013 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | 9-HODE | 2.4 picomoles per milliliter | Standard Deviation 1.9 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | 13-HODE | 5.2 picomoles per milliliter | Standard Deviation 3.9 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | 13-HOTrE | 1.5 picomoles per milliliter | Standard Deviation 1.4 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | 5-HETE | 0.023 picomoles per milliliter | Standard Deviation 0.018 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | 8-HETE | 0.14 picomoles per milliliter | Standard Deviation 0.061 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | 9-HETE | 0.029 picomoles per milliliter | Standard Deviation 0.018 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | 11-HETE | 0.012 picomoles per milliliter | Standard Deviation 0.0061 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | 12-HETE | 0.04 picomoles per milliliter | Standard Deviation 0.031 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | 15-HETE | 0.074 picomoles per milliliter | Standard Deviation 0.054 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | 12-HEPE | 0.029 picomoles per milliliter | Standard Deviation 0.015 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | 9,10-e-DiHO | 21 picomoles per milliliter | Standard Deviation 12 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | 9,10-DiHOME | 3.1 picomoles per milliliter | Standard Deviation 1.8 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | 12,13-DiHOME | 2.8 picomoles per milliliter | Standard Deviation 1.6 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | 9,10-DiHODE | 0.56 picomoles per milliliter | Standard Deviation 0.68 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | 12,13-DiHODE | 0.3 picomoles per milliliter | Standard Deviation 0.12 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | 15,16-DiHODE | 1.9 picomoles per milliliter | Standard Deviation 2.3 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | 5,6-DiHETrE | 0.026 picomoles per milliliter | Standard Deviation 0.037 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | 9,10-EpOME | 0.46 picomoles per milliliter | Standard Deviation 0.31 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | 12,13-EpOME | 0.36 picomoles per milliliter | Standard Deviation 0.22 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | 9-KODE | 1.5 picomoles per milliliter | Standard Deviation 1.4 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | 13-KODE | 0.89 picomoles per milliliter | Standard Deviation 0.6 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | 12,13-Ep-9-KODE | 3.4 picomoles per milliliter | Standard Deviation 1.8 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | 5-KETE | 0.02 picomoles per milliliter | Standard Deviation 0.017 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | LTB5 | 0.099 picomoles per milliliter | Standard Deviation 0.082 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | 10-Nitrooleate | 0.074 picomoles per milliliter | Standard Deviation 0.043 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | PGE2 | 1.1 picomoles per milliliter | Standard Deviation 1.3 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | PGE3 | 0.18 picomoles per milliliter | Standard Deviation 0.21 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | Sum TriHOMEs | 130 picomoles per milliliter | Standard Deviation 130 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | PEA | 14 picomoles per milliliter | Standard Deviation 25 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | SEA | 15 picomoles per milliliter | Standard Deviation 25 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | OEA | 0.11 picomoles per milliliter | Standard Deviation 0.093 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | LEA | 0.019 picomoles per milliliter | Standard Deviation 0.01 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | aLEA | 0.0033 picomoles per milliliter | Standard Deviation 0.0024 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | 1-OG | 11 picomoles per milliliter | Standard Deviation 14 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | 2-OG | 7 picomoles per milliliter | Standard Deviation 7.3 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | 1-LG | 2.1 picomoles per milliliter | Standard Deviation 1.8 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | 2-LG | 0.34 picomoles per milliliter | Standard Deviation 0.36 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | 1-AG | 1.8 picomoles per milliliter | Standard Deviation 3.1 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | 2-AG | 0.79 picomoles per milliliter | Standard Deviation 1 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | NO-Gly | 0.15 picomoles per milliliter | Standard Deviation 0.13 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | NA-Gly | 0.01 picomoles per milliliter | Standard Deviation 0.012 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | C14 Ceramide | 0.23 picomoles per milliliter | Standard Deviation 0.18 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | C16 Ceramide | 1 picomoles per milliliter | Standard Deviation 1 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | C18 Ceramide | 0.29 picomoles per milliliter | Standard Deviation 0.34 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | C20 Ceramide | 0.36 picomoles per milliliter | Standard Deviation 0.34 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | C24 Ceramide | 0.88 picomoles per milliliter | Standard Deviation 0.8 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | 18:1 Sphingosine | 4.9 picomoles per milliliter | Standard Deviation 4.6 |
Primary
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
Approximately 150 lipid mediators will be measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Assayed lipid mediators include oxygenated lipids, endocannabinoids and endocannabinoid-like molecules, and sphingolipids.
Time frame: measured at study visit 1, 2 and 3; detected lipid mediator concentrations for study visit 1 reported
Population: Of the 14 subjects recruited for this study, only 7 provided usable data for this primary outcome.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 5-HETE | 0.1 picomoles per milliliter | Standard Deviation 0.07 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 8-HETE | 0.23 picomoles per milliliter | Standard Deviation 0.062 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 12-HETE | 0.85 picomoles per milliliter | Standard Deviation 0.94 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 15-HETE | 0.43 picomoles per milliliter | Standard Deviation 0.25 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 12-HEPE | 0.086 picomoles per milliliter | Standard Deviation 0.044 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 9,10-e-DiHO | 85 picomoles per milliliter | Standard Deviation 37 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 9,10-DiHOME | 4.4 picomoles per milliliter | Standard Deviation 3 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 12,13-DiHOME | 3.4 picomoles per milliliter | Standard Deviation 2.3 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 9,10-DiHODE | 0.85 picomoles per milliliter | Standard Deviation 1.1 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 12,13-DiHODE | 0.5 picomoles per milliliter | Standard Deviation 0.31 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 15,16-DiHODE | 2.7 picomoles per milliliter | Standard Deviation 3.9 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 5,6-DiHETrE | 5.3 picomoles per milliliter | Standard Deviation 2.5 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 8,9-DiHETrE | 0.73 picomoles per milliliter | Standard Deviation 0.43 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 11,12-DiHETrE | 0.51 picomoles per milliliter | Standard Deviation 0.29 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 14,15-DiHETrE | 0.65 picomoles per milliliter | Standard Deviation 0.4 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 9,10-EpOME | 1.7 picomoles per milliliter | Standard Deviation 0.79 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 12,13-EpODE | 0.12 picomoles per milliliter | Standard Deviation 0.066 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 15,16-EpODE | 3.5 picomoles per milliliter | Standard Deviation 3.4 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 9-KODE | 14 picomoles per milliliter | Standard Deviation 6.3 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 15-deoxy PGJ2 | 0.033 picomoles per milliliter | Standard Deviation 0.012 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | PGE3 | 0.13 picomoles per milliliter | Standard Deviation 0.17 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | Sum TriHOMEs | 57 picomoles per milliliter | Standard Deviation 56 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | SEA | 7.9 picomoles per milliliter | Standard Deviation 6.7 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 9-HODE | 20 picomoles per milliliter | Standard Deviation 9.8 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 13-HODE | 46 picomoles per milliliter | Standard Deviation 28 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 9-HOTrE | 2.2 picomoles per milliliter | Standard Deviation 1.2 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 13-HOTrE | 3.5 picomoles per milliliter | Standard Deviation 1.8 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 9-HETE | 0.12 picomoles per milliliter | Standard Deviation 0.062 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 11-HETE | 0.15 picomoles per milliliter | Standard Deviation 0.055 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 12,13-EpOME | 0.96 picomoles per milliliter | Standard Deviation 0.29 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 9,10-EpODE | 0.55 picomoles per milliliter | Standard Deviation 0.54 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 13-KODE | 7.2 picomoles per milliliter | Standard Deviation 3.8 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 12,13-Ep-9-KODE | 3.7 picomoles per milliliter | Standard Deviation 2.8 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 5-KETE | 0.025 picomoles per milliliter | Standard Deviation 0.019 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | LTB5 | 0.1 picomoles per milliliter | Standard Deviation 0.094 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 10-Nitrooleate | 0.096 picomoles per milliliter | Standard Deviation 0.054 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 10-Nitrolinoleate | 0.11 picomoles per milliliter | Standard Deviation 0.069 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | PGE1 | 0.24 picomoles per milliliter | Standard Deviation 0.15 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | PGE2 | 2.1 picomoles per milliliter | Standard Deviation 1.8 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | PGF2a | 0.14 picomoles per milliliter | Standard Deviation 0.14 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | PEA | 7.9 picomoles per milliliter | Standard Deviation 6.8 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | OEA | 0.32 picomoles per milliliter | Standard Deviation 0.38 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | LEA | 0.043 picomoles per milliliter | Standard Deviation 0.035 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | aLEA | 0.0047 picomoles per milliliter | Standard Deviation 0.0036 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | Dihomo GLA EA | 0.0022 picomoles per milliliter | Standard Deviation 0.003 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | AEA | 0.019 picomoles per milliliter | Standard Deviation 0.011 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | DEA | 0.17 picomoles per milliliter | Standard Deviation 0.24 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 1-OG | 870 picomoles per milliliter | Standard Deviation 1300 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 2-OG | 190 picomoles per milliliter | Standard Deviation 270 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 1-LG | 300 picomoles per milliliter | Standard Deviation 540 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 2-LG | 2.3 picomoles per milliliter | Standard Deviation 1.1 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 1-AG | 14 picomoles per milliliter | Standard Deviation 12 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 2-AG | 15 picomoles per milliliter | Standard Deviation 30 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | NO-Gly | 0.48 picomoles per milliliter | Standard Deviation 0.22 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | NA-Gly | 0.017 picomoles per milliliter | Standard Deviation 0.02 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | C14 Ceramide | 1.4 picomoles per milliliter | Standard Deviation 1.1 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | C16 Ceramide | 6.6 picomoles per milliliter | Standard Deviation 4.7 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | C18 Ceramide | 1.2 picomoles per milliliter | Standard Deviation 0.66 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | C20 Ceramide | 2 picomoles per milliliter | Standard Deviation 1.4 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | C24 Ceramide | 5.7 picomoles per milliliter | Standard Deviation 4.9 |
| Single Group | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | 18:1 Sphingosine | 15 picomoles per milliliter | Standard Deviation 8.9 |
Secondary
Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
Approximately 100 lipid mediators will be measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Assayed lipid mediators include oxygenated lipids, endocannabinoids, and endocannabinoid-like molecules.
Time frame: measured at four timepoints at study visit 4, detected lipid mediator concentrations for first timepoint reported
Population: Of the 14 subjects recruited for this study, only 9 provided usable data for this primary outcome.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Single Group | Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 20-HETE | 0.742 picomoles per milliliter |
| Single Group | Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 15-HETE | 0.311 picomoles per milliliter |
| Single Group | Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 12-HEPE | 0.0781 picomoles per milliliter |
| Single Group | Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 15,16-DiHODE | 1.49 picomoles per milliliter |
| Single Group | Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 9(10)-EpOME | 0.657 picomoles per milliliter |
| Single Group | Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | OEA | 0.586 picomoles per milliliter |
| Single Group | Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | NO-Gly | 0.156 picomoles per milliliter |
| Single Group | Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | PGE1 | 0.453 picomoles per milliliter |
| Single Group | Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | PGE2 | 2.71 picomoles per milliliter |
| Single Group | Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 13-HODE | 21.9 picomoles per milliliter |
| Single Group | Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 9-HODE | 7.72 picomoles per milliliter |
| Single Group | Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 13-HOTE | 1.08 picomoles per milliliter |
| Single Group | Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 9-HOTE | 1.08 picomoles per milliliter |
| Single Group | Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 12-HETE | 0.965 picomoles per milliliter |
| Single Group | Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 11-HETE | 0.0882 picomoles per milliliter |
| Single Group | Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 8-HETE | 0.0618 picomoles per milliliter |
| Single Group | Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 5-HETE | 0.138 picomoles per milliliter |
| Single Group | Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 15-HEPE | 0.0576 picomoles per milliliter |
| Single Group | Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 17-HDoHE | 0.46 picomoles per milliliter |
| Single Group | Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 9,10-e-DiHO | 58.4 picomoles per milliliter |
| Single Group | Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 12,13-DiHOME | 1.89 picomoles per milliliter |
| Single Group | Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 9,10-DiHOME | 3.61 picomoles per milliliter |
| Single Group | Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 12,13-DiHODE | 0.332 picomoles per milliliter |
| Single Group | Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 9,10-DiHODE | 0.35 picomoles per milliliter |
| Single Group | Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 14,15-DiHETrE | 0.341 picomoles per milliliter |
| Single Group | Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 11,12-DiHETrE | 0.231 picomoles per milliliter |
| Single Group | Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 5,6-DiHETrE | 3.29 picomoles per milliliter |
| Single Group | Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 17,18-DiHETE | 1.76 picomoles per milliliter |
| Single Group | Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | Sum TriHOMEs | 31.7 picomoles per milliliter |
| Single Group | Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 9(10)-EpO | 2.81 picomoles per milliliter |
| Single Group | Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 12(13)-EpOME | 0.485 picomoles per milliliter |
| Single Group | Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 15(16)-EpODE | 0.491 picomoles per milliliter |
| Single Group | Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 12(13)-EpODE | 0.0703 picomoles per milliliter |
| Single Group | Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 9(10)-EpODE | 0.194 picomoles per milliliter |
| Single Group | Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 13-KODE | 2.17 picomoles per milliliter |
| Single Group | Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 9-KODE | 5.35 picomoles per milliliter |
| Single Group | Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 12(13)-Ep-9-KODE | 1.82 picomoles per milliliter |
| Single Group | Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 10-Nitrooleate | 1.78 picomoles per milliliter |
| Single Group | Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 9-Nitrooleate | 0.729 picomoles per milliliter |
| Single Group | Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | 10-Nitrolinoleate | 0.297 picomoles per milliliter |
| Single Group | Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | LEA | 0.0447 picomoles per milliliter |
| Single Group | Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | NA-Gly | 0.0627 picomoles per milliliter |
| Single Group | Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | OG | 61.5 picomoles per milliliter |
| Single Group | Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | LG | 4.11 picomoles per milliliter |
| Single Group | Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | AG | 4.2 picomoles per milliliter |
Secondary
Change in Plasma Ibuprofen Concentrations
Plasma concentration of ibuprofen prior to and 30 min, 2 hr and 4 hr after oral administration
Time frame: measured at four timepoints at study visit 4
Population: Of the 14 subjects recruited for this study, only 9 provided usable data for this primary outcome.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Single Group | Change in Plasma Ibuprofen Concentrations | Prior to administration | 0 micrograms per milliliter |
| Single Group | Change in Plasma Ibuprofen Concentrations | 2 hr after administration | 48.3 micrograms per milliliter |
| Single Group | Change in Plasma Ibuprofen Concentrations | 4 hr after administration | 33.8 micrograms per milliliter |
| Single Group | Change in Plasma Ibuprofen Concentrations | 30 min after administration | 18.8 micrograms per milliliter |
Secondary
Change in Sweat Ibuprofen Concentrations
Sweat concentration of ibuprofen prior to and 30 min, 2 hr and 4 hr after oral administration
Time frame: measured at four timepoints at study visit 4
Population: Of the 14 subjects recruited for this study, only 9 provided usable data for this primary outcome.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Single Group | Change in Sweat Ibuprofen Concentrations | Prior to administration | 0 micrograms per milliliter |
| Single Group | Change in Sweat Ibuprofen Concentrations | 30 min after administration | 0 micrograms per milliliter |
| Single Group | Change in Sweat Ibuprofen Concentrations | 2 hr after administration | 0 micrograms per milliliter |
| Single Group | Change in Sweat Ibuprofen Concentrations | 4 hr after administration | 0 micrograms per milliliter |